The glutathione injection market is experiencing unprecedented growth in 2025, with industry reports documenting a significant surge in demand for these treatments, particularly for cosmetic purposes
Santos P, Herrmann AP, Elisabetsky E, Piato A
Palomba S, Santagni S, La Sala GB
Tirzepatide is a dual-agonist , meaning it works by targeting two hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Retatrutide is a triple-agonist , meaning it targets three hormones: GLP-1: helps regulate appetite, blood sugar, and digestion GIP: supports insulin response and reduces nausea Glucagon: affects energy use and fat metabolism Early studies show that retatrutide may be more successful than tirzepatide at managing diabetic kidney disease, as well as for weight control, while tirzepatide may be better at managing blood glucose